The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 06, 2018

Filed:

Sep. 26, 2016
Applicant:

Alderbio Holdings Llc, Las Vegas, NV (US);

Inventors:

Leon Garcia-Martinez, Woodinville, WA (US);

Anne Elisabeth Carvalho Jensen, Wenatchee, WA (US);

Katie Olson Anderson, Kirkland, WA (US);

Benjamin H. Dutzar, Seattle, WA (US);

John A. Latham, Seattle, WA (US);

Brian R. Kovacevich, Snohomish, WA (US);

Jeffrey T. L. Smith, Bellevue, WA (US);

Mark Litton, Seattle, WA (US);

Randall C. Schatzman, Redmond, WA (US);

Assignee:

ALDERBIO HOLDINGS LLC, Las Vegas, NV (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
G01N 33/68 (2006.01); C07K 16/24 (2006.01); A61K 51/10 (2006.01); A61K 49/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 51/1033 (2013.01); A61K 49/0058 (2013.01); C07K 16/248 (2013.01); G01N 33/6869 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2333/5412 (2013.01); G01N 2800/7095 (2013.01); Y02A 50/412 (2018.01);
Abstract

The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.


Find Patent Forward Citations

Loading…